EGFR and non-small cell lung carcinoma: Erlotinib, a first-generation EGFR tyrosine kinase inhibitor (TKI) was used as neoadjuvant therapy in CTONG1103 and has been shown to improve the median progression-free survival from 11.4 months to 21.5 months among patients with EGFR mutant Stage IIIA (N2) NSCLC compared with chemotherapy (10).